Why GT Biopharma’s B7-H3 TriKE could reshape immunotherapy for solid tumors
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
Relay Therapeutics secures FDA breakthrough designation for zovegalisib in PIK3CA-mutant HR+/HER2- advanced breast cancer
FDA grants breakthrough therapy designation to Relay Therapeutics’ zovegalisib. Find out what this changes for PI3K-mutant breast cancer treatment.
How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.
What Theriva Biologics’ APAO 2026 presentation signals for intravitreal oncology treatments
Theriva’s APAO 2026 VCN-01 data reveals how viral synergy and local delivery could redefine pediatric eye cancer care.
Could Invivyd’s VYD2311 offer a safer alternative to mRNA COVID vaccines for vulnerable groups?
Invivyd’s LIBERTY trial could reshape COVID prophylaxis by comparing VYD2311 antibody safety with mRNA vaccines. See what’s at stake for regulators.
What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
Can ALK-Abelló’s EURneffy launch shift real-world adoption of non-injectable adrenaline in EU schools?
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Why Sixty Degrees Pharmaceuticals is betting on retail channels for tafenoquine adoption
Tafenoquine’s retail debut via GoodRx marks a shift in malaria prevention access. Find out what this means for U.S. travel medicine strategy.
What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
Why Scilex Holding Company sees strategic optionality in diagnostic platforms beyond traditional therapeutics
Explore what Scilex Holding Company’s $20M Quantum Scan investment means for preventive diagnostics and the execution risks ahead.